NZ591945A - Disubstituted phthalazine hedgehog pathway antagonists - Google Patents
Disubstituted phthalazine hedgehog pathway antagonistsInfo
- Publication number
- NZ591945A NZ591945A NZ591945A NZ59194509A NZ591945A NZ 591945 A NZ591945 A NZ 591945A NZ 591945 A NZ591945 A NZ 591945A NZ 59194509 A NZ59194509 A NZ 59194509A NZ 591945 A NZ591945 A NZ 591945A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- fluorophenyl
- hydrogen
- fluoro
- compounds
- Prior art date
Links
- 241000289669 Erinaceus europaeus Species 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- -1 difluoromethoxy, methoxy Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- BPOQPMSRUDFRCM-URBRKQAFSA-N (2s,5r)-n-(4-fluorophenyl)-4-[4-(4-fluorophenyl)phthalazin-1-yl]-2,5-dimethylpiperazine-1-carboxamide;hydrochloride Chemical compound Cl.C([C@@H](C)N(C[C@@H]1C)C=2C3=CC=CC=C3C(C=3C=CC(F)=CC=3)=NN=2)N1C(=O)NC1=CC=C(F)C=C1 BPOQPMSRUDFRCM-URBRKQAFSA-N 0.000 abstract 1
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 1
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 201000009036 biliary tract cancer Diseases 0.000 abstract 1
- 208000020790 biliary tract neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- VWVTVUOMKSFMFG-UHFFFAOYSA-N n-(4-cyanophenyl)-2-methyl-4-(4-phenylphthalazin-1-yl)piperazine-1-carboxamide;hydrochloride Chemical compound Cl.CC1CN(C=2C3=CC=CC=C3C(C=3C=CC=CC=3)=NN=2)CCN1C(=O)NC1=CC=C(C#N)C=C1 VWVTVUOMKSFMFG-UHFFFAOYSA-N 0.000 abstract 1
- VGVMZZXUJBGLCX-UHFFFAOYSA-N n-(4-fluorophenyl)-4-[4-(4-fluorophenyl)phthalazin-1-yl]-2-(hydroxymethyl)piperazine-1-carboxamide;hydrochloride Chemical compound Cl.OCC1CN(C=2C3=CC=CC=C3C(C=3C=CC(F)=CC=3)=NN=2)CCN1C(=O)NC1=CC=C(F)C=C1 VGVMZZXUJBGLCX-UHFFFAOYSA-N 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000000587 small cell lung carcinoma Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11070308P | 2008-11-03 | 2008-11-03 | |
| PCT/US2009/061573 WO2010062507A1 (en) | 2008-11-03 | 2009-10-22 | Disubstituted phthalazine hedgehog pathway antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ591945A true NZ591945A (en) | 2012-10-26 |
Family
ID=41566219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ591945A NZ591945A (en) | 2008-11-03 | 2009-10-22 | Disubstituted phthalazine hedgehog pathway antagonists |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8404687B2 (enExample) |
| EP (1) | EP2364185B1 (enExample) |
| JP (1) | JP2012507535A (enExample) |
| KR (1) | KR101335746B1 (enExample) |
| CN (1) | CN102202737B (enExample) |
| AU (1) | AU2009320251C1 (enExample) |
| BR (1) | BRPI0921437A2 (enExample) |
| CA (1) | CA2742539C (enExample) |
| CL (1) | CL2011000979A1 (enExample) |
| CO (1) | CO6382123A2 (enExample) |
| CR (1) | CR20110202A (enExample) |
| CY (1) | CY1114023T1 (enExample) |
| DK (1) | DK2364185T3 (enExample) |
| EA (1) | EA018931B1 (enExample) |
| EC (1) | ECSP11011021A (enExample) |
| ES (1) | ES2418479T3 (enExample) |
| HR (1) | HRP20130527T1 (enExample) |
| IL (1) | IL211841A0 (enExample) |
| MA (1) | MA32726B1 (enExample) |
| MX (1) | MX2011004683A (enExample) |
| NZ (1) | NZ591945A (enExample) |
| PE (1) | PE20110433A1 (enExample) |
| PL (1) | PL2364185T3 (enExample) |
| PT (1) | PT2364185E (enExample) |
| SI (1) | SI2364185T1 (enExample) |
| TN (1) | TN2011000166A1 (enExample) |
| UA (1) | UA102115C2 (enExample) |
| WO (1) | WO2010062507A1 (enExample) |
| ZA (1) | ZA201102448B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5550352B2 (ja) * | 2007-03-15 | 2014-07-16 | ノバルティス アーゲー | 有機化合物およびその使用 |
| EA201071248A1 (ru) | 2008-04-29 | 2011-06-30 | Эли Лилли Энд Компани | Дизамещенные фталазиновые антагонисты пути hedgehog |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| BRPI0921782A2 (pt) | 2008-11-17 | 2019-09-24 | Lilly Co Eli | antagonistas da via hedgehog de piridazina tetrassubstituída |
| AU2009314288B2 (en) | 2008-11-17 | 2013-05-02 | Eli Lilly And Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
| US9814703B2 (en) | 2013-11-14 | 2017-11-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of BMP signaling |
| CN105985321B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 吡唑酞嗪化合物及其制备方法和用途 |
| CN105985319B (zh) * | 2015-02-11 | 2019-02-26 | 复旦大学 | 芳基酞嗪化合物及其制备方法和用途 |
| CN105985320B (zh) * | 2015-02-11 | 2018-10-26 | 复旦大学 | 苄基酞嗪化合物及其制备方法和用途 |
| WO2022081661A1 (en) | 2020-10-13 | 2022-04-21 | Endeavor Biomedicines, Inc. | Methods of treating fibrosis |
| IL319619A (en) * | 2022-09-23 | 2025-05-01 | Merck Sharp & Dohme Llc | Phthalazine derivatives used as NOD-LIKE PROTEIN 3 receptor inhibitors |
| WO2025188802A1 (en) | 2024-03-05 | 2025-09-12 | Endeavor Biomedicines, Inc. | Methods of improving lung function |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1293565A (en) | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
| CA2237273C (en) | 1996-01-15 | 2009-01-13 | Janssen Pharmaceutica N.V. | Angiogenesis inhibiting pyridazinamines |
| AU719392B2 (en) * | 1996-10-01 | 2000-05-11 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compounds |
| US6432970B2 (en) | 1998-04-09 | 2002-08-13 | Johns Hopkins University School Of Medicine | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
| EP1067939B1 (en) | 1998-04-09 | 2015-09-16 | The Johns Hopkins University | Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways |
| GB0013674D0 (en) | 1999-06-08 | 2000-07-26 | Lorantis Ltd | Therapeutic use |
| ATE404200T1 (de) | 2002-04-22 | 2008-08-15 | Univ Johns Hopkins Med | Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen |
| WO2004020599A2 (en) | 2002-08-29 | 2004-03-11 | Curis, Inc. | Hedgehog antagonists, methods and uses related thereto |
| WO2005033288A2 (en) * | 2003-09-29 | 2005-04-14 | The Johns Hopkins University | Hedgehog pathway antagonists |
| TW200533356A (en) | 2004-02-24 | 2005-10-16 | Mitsubishi Pharma Corp | Fused pyridazine derivatives |
| US8338591B2 (en) | 2004-05-08 | 2012-12-25 | Novartis International Pharmaceutical Ltd. | 3-aryl-5,6-disubstituted pyridazines |
| KR20170001725A (ko) * | 2004-09-02 | 2017-01-04 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
| EP1900731A1 (de) | 2006-09-07 | 2008-03-19 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren |
| JP5550352B2 (ja) * | 2007-03-15 | 2014-07-16 | ノバルティス アーゲー | 有機化合物およびその使用 |
| AU2008269128B2 (en) | 2007-06-25 | 2012-08-02 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| WO2009035568A1 (en) | 2007-09-07 | 2009-03-19 | Amgen Inc. | Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling |
| EA201071248A1 (ru) | 2008-04-29 | 2011-06-30 | Эли Лилли Энд Компани | Дизамещенные фталазиновые антагонисты пути hedgehog |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| AU2009314288B2 (en) | 2008-11-17 | 2013-05-02 | Eli Lilly And Company | Tetrasubstituted pyridazines hedgehog pathway antagonists |
| BRPI0921782A2 (pt) | 2008-11-17 | 2019-09-24 | Lilly Co Eli | antagonistas da via hedgehog de piridazina tetrassubstituída |
| AR077014A1 (es) | 2009-06-19 | 2011-07-27 | Lilly Co Eli | Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer |
-
2009
- 2009-10-22 NZ NZ591945A patent/NZ591945A/xx not_active IP Right Cessation
- 2009-10-22 CA CA2742539A patent/CA2742539C/en not_active Expired - Fee Related
- 2009-10-22 HR HRP20130527AT patent/HRP20130527T1/hr unknown
- 2009-10-22 PT PT97406136T patent/PT2364185E/pt unknown
- 2009-10-22 DK DK09740613.6T patent/DK2364185T3/da active
- 2009-10-22 PE PE2011000937A patent/PE20110433A1/es not_active Application Discontinuation
- 2009-10-22 CN CN200980143394.3A patent/CN102202737B/zh not_active Expired - Fee Related
- 2009-10-22 ES ES09740613T patent/ES2418479T3/es active Active
- 2009-10-22 AU AU2009320251A patent/AU2009320251C1/en not_active Ceased
- 2009-10-22 SI SI200930625T patent/SI2364185T1/sl unknown
- 2009-10-22 MX MX2011004683A patent/MX2011004683A/es active IP Right Grant
- 2009-10-22 WO PCT/US2009/061573 patent/WO2010062507A1/en not_active Ceased
- 2009-10-22 BR BRPI0921437A patent/BRPI0921437A2/pt not_active IP Right Cessation
- 2009-10-22 PL PL09740613T patent/PL2364185T3/pl unknown
- 2009-10-22 UA UAA201105364A patent/UA102115C2/ru unknown
- 2009-10-22 JP JP2011534624A patent/JP2012507535A/ja active Pending
- 2009-10-22 KR KR1020117010063A patent/KR101335746B1/ko not_active Expired - Fee Related
- 2009-10-22 US US13/122,212 patent/US8404687B2/en not_active Expired - Fee Related
- 2009-10-22 EP EP09740613.6A patent/EP2364185B1/en active Active
- 2009-10-22 EA EA201170640A patent/EA018931B1/ru not_active IP Right Cessation
-
2011
- 2011-03-21 IL IL211841A patent/IL211841A0/en unknown
- 2011-04-01 ZA ZA2011/02448A patent/ZA201102448B/en unknown
- 2011-04-07 TN TN2011000166A patent/TN2011000166A1/fr unknown
- 2011-04-15 CR CR20110202A patent/CR20110202A/es not_active Application Discontinuation
- 2011-04-22 MA MA33790A patent/MA32726B1/fr unknown
- 2011-05-02 EC EC2011011021A patent/ECSP11011021A/es unknown
- 2011-05-02 CL CL2011000979A patent/CL2011000979A1/es unknown
- 2011-05-11 CO CO11058054A patent/CO6382123A2/es active IP Right Grant
-
2013
- 2013-06-05 CY CY20131100447T patent/CY1114023T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ591945A (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| TW200618800A (en) | Heterocyclic compounds | |
| NZ596882A (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| MX2009012709A (es) | Derivados de arileter-piridazinona. | |
| JP2011527666A5 (enExample) | ||
| PH12020551278A1 (en) | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer | |
| MX2009012708A (es) | Derivados de piridazinona. | |
| MY148322A (en) | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors | |
| IL266563B (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| CY1118498T1 (el) | Παραγωγα πυριδαζινονης | |
| SG170739A1 (en) | Iap bir domain binding compounds | |
| NZ608667A (en) | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | |
| WO2008057775A3 (en) | Heterocyclic amide compounds useful as kinase inhibitors | |
| MX2009009699A (es) | Compuestos amino-5-[4-(difluorometoxi)fenil sustituidos]-5-fenilim idazolona como inhibidores de beta-secretasa. | |
| WO2008016192A3 (en) | Fused heterocyclic derivative and use thereof | |
| GEP201706691B (en) | Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1 | |
| IN2012DN00573A (enExample) | ||
| NZ595553A (en) | VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol | |
| PE20171338A1 (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| ES2662444T3 (es) | Derivado de piridina | |
| NZ598582A (en) | Novel phenol derivative having uricsuric effect | |
| JP2014507464A5 (enExample) | ||
| TW200728277A (en) | Bicyclic derivatives as P38 inhibitors | |
| UA107675C2 (xx) | Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом | |
| MX2010003365A (es) | Derivados de tiazol para el tratamiento de cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 OCT 2016 BY THOMSON REUTERS Effective date: 20130920 |
|
| LAPS | Patent lapsed |